Monitor regulatory approval process and any updates on final consideration. The sale frees up capital for BWXT's core nuclear businesses, which could drive near-term re-rating. Watch for potential share buybacks or reinvestment announcements.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $172.40entry
- T+1 · 3mo ago −2.39%α −2.19% · $168.28
- T+5 · 3mo ago −1.56%α −1.46% · $169.71
- T+20 · 3mo ago −6.30%α −5.06% · $161.54
- T+60 · 19d ago −22.23%α −22.02% · $134.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BWX Technologies has agreed to sell its medical business to Nordic Capital for up to $800 million, retaining a minority stake. The divestiture allows BWXT to refocus capital and resources on its core nuclear national security and commercial nuclear power markets, while the medical business gains a dedicated healthcare investor.
Key Financial Metrics
Key Facts
- BWXT sells its medical business (BWXT Medical and Kinectrics' stable medical isotopes) to Nordic Capital for up to $800 million.
- BWXT will retain a meaningful minority ownership stake in the divested business.
- Transaction expected to close by end of 2026, subject to customary regulatory approvals.
- Sale enables BWXT to concentrate on core nuclear national security and commercial nuclear power growth.
Financial Impact
Up to $800 million cash consideration, plus retained minority stake; deal value represents ~5% of BWXT's $15.5B market cap.
Risk Factors
- Regulatory approval delays or conditions reducing deal value.
- Lower than expected final consideration if earn-out conditions not met.
- Execution risk in reallocating capital to core growth areas.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302841634 |
Track record
11 reports on BWXT
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +26.17% at T+60 after the Aug 15, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $122.97 Now $117.09 −4.78% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $114.96 to $123.99 Now $117.09 +1.85% ▲ +7.85% +4.56% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $121.50 to $125.68 Now $117.09 −3.63% ▲ +3.44% +4.35% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $131.82 to $126.64 Now $117.09 −11.17% ▼ −3.93% −3.34% vs SPY
- Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $127.19 to $130.70 Now $117.09 −7.94% ▲ +2.76% +3.32% vs SPY
- Aug 15, 202613w ago Institutional Cluster Bearish 5/10 Entry $171.54 to $149.52 Now $117.09 +31.74% ▲ +12.84% +11.65% vs SPY
- Aug 12, 202613w ago 144 Neutral 2/10 Entry $170.35 to $156.44 Now $117.09 −31.27% ▼ −8.17% −6.20% vs SPY
- Aug 3, 202615w ago Press Release Bullish 6/10 Viewing Entry $172.40 to $169.71 Now $117.09 −32.08% ▼ −1.56% −1.46% vs SPY
- Jul 23, 202616w ago GOVT-CONTRACT Neutral 4/10 Entry $174.52 to $168.70 Now $117.09 −32.91% ▼ −3.33% −4.43% vs SPY
- May 4, 202628w ago 8-K Bullish 7/10 Entry $206.15 to $210.80 Now $117.09 −43.20% ▲ +2.26% +0.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers